Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a meningioma (a type of brain tumour) confirmed by tissue testing, specifically World Health Organization (WHO) grade 1, 2, or 3.
• People whose tumour has come back or continued to grow after standard treatments such as surgery and/or radiation, or who have been assessed as unable to receive those treatments.
• People who have received at least one course of radiation therapy directed at the meningioma, unless radiation was not medically appropriate for them.
• People whose tumour has been shown on scans to have grown by more than 15% in two dimensions within the past 6 months, or who have developed new tumour spots.
• People who had external beam radiation, brachytherapy, or radiosurgery must have finished that treatment at least 24 weeks before starting this trial.
• People who have measurable tumour activity on scans, assessed within 14 days before starting treatment, as determined by the trial investigator.
• People who have a performance status score of 60% or higher on the Karnofsky scale, which means they are able to care for themselves and carry out some normal activities (confirm with trial site).
• People who have adequately functioning organs and bone marrow, confirmed by tests done within 14 days before starting treatment.

Who may not be able to join:

• People who have ever had a condition called hypertensive encephalopathy (a serious complication of very high blood pressure affecting the brain).
• People who have tumour growths outside the brain that are pressing into or invading major blood vessels such as the main vein returning blood to the heart, the main artery from the heart, or the lung's main blood vessel.
• People who are unable to have an MRI scan for any reason.
• People for whom the treating doctor determines that surgery or radiation is the appropriate next treatment.
• People who have received cancer-fighting drugs, biological therapies, or other systemic anticancer treatments (including experimental ones) within 4 weeks or 5 half-lives of the drug — whichever period is shorter — before starting the trial.
• People who have had major surgery within the past 8 weeks, or minor surgery (including brain biopsies) within the past 7 days, and whose surgical wound has not fully healed.
• People with serious uncontrolled ongoing or recent illnesses, including uncontrolled high blood pressure, certain stomach or bowel conditions with a high risk of tearing or abnormal connections forming, significant recent bleeding (including in the brain), or other serious medical conditions.
• People who require kidney dialysis (either haemodialysis or peritoneal dialysis).
• People who have previously received a transplanted solid organ or stem cells from a donor.

Important: Always verify eligibility with the trial site directly before applying.